All In Biotech

Drug Trial Radar · NCT04045496

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 26, 2019

Primary completion

Dec 16, 2022

Study completion Dec 16, 2022

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

Conditions

  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Carcinoma
  • Esophageal Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Breast Cancer
  • Other Solid Tumors

Interventions

  • JAB-3312Drug

    JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: Approximately 2 years
  2. Find Recommended Phase 2 Dose (RP2D) of JAB-3312Time frame: Approximately 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • HealthONE Clinic Services Oncology-Hematology

    Denver, Colorado

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas

  • Washington University School of Medicine

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.